A New Strategy for Treatment of Autoimmune Diseases in Chimeric Resistant MRL/lpr Mice by Kenji Takeuchi, Muneo Inaba, Shigeo Miyashima, Ryokei Ogawa,

Slides:

Advertisements

Similar presentations

Heather J. Symons, Moshe Y

Advertisements

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative.

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation Qing Ma, Dan Li, Roza Nurieva, Rebecca.

Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact.

Probiotic effects on experimental graft-versus-host disease: let them eat yogurt by Armin Gerbitz, Michael Schultz, Andrea Wilke, Hans-Jörg Linde, Jürgen.

Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure by Jichun Chen, Karen Lipovsky,

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.

Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.

Expression of Chemokines in GVHD Target Organs Is Influenced by Conditioning and Genetic Factors and Amplified by GVHR Markus Y. Mapara, Corinna Leng,

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease Robert Zeiser,

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer.

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers by Andrea.

Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver Alina Schreder,

by Yoshinobu Maeda, Pavan Reddy, Kathleen P

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging by Matthias Edinger, Yu-An Cao, Michael R. Verneris,

IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation by Christoph Bucher, Lisa Koch, Christine.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,

by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A

PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model) Yehudith Azar, Reut.

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major by Yongliang Huo, Jonathan R. Lockhart,

Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.

Expression of connexin 43 (Cx43) is critical for normal hematopoiesis

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.

Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.

by Xue Li, Jared Sipple, Qishen Pang, and Wei Du

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Sequential Expression of Adhesion and Costimulatory Molecules in Graft-versus-Host Disease Target Organs after Murine Bone Marrow Transplantation across.

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative.

Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W

Volume 87, Issue 5, Pages (May 2015)

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Susumu Ikehara Experimental Hematology

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft- versus-Host Disease Scott S. Graves, Maura H. Parker, Diane Stone,

T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.

Mark J. Kiel, Melih Acar, Glenn L. Radice, Sean J. Morrison

Nrf2-deficient female mice develop lupus-like autoimmune nephritis1

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease Haruko Sugiyama,

Yang Xu, Genhong Cheng, David Baltimore Immunity

Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease Xiao Chen, Rupali Das, Richard Komorowski,

Volume 27, Issue 3, Pages (September 2007)

Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells Christian Scheffold, Yolanda C. Scheffold,

Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation Jian-Ming Li, Edmund K.

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution Maria Gendelman, Maryam Yassai,

Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease Wonyoung Kim, Juyang.

Volume 58, Issue 5, Pages (November 2000)

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Anti-PD-1H Antibody Prevents Graft Versus Host Disease

by Samuel J. Taylor, Johanna M. Duyvestyn, Samantha A. Dagger, Emma J

Alicia G Arroyo, Joy T Yang, Helen Rayburn, Richard O Hynes Cell

Presentation transcript:

A New Strategy for Treatment of Autoimmune Diseases in Chimeric Resistant MRL/lpr Mice by Kenji Takeuchi, Muneo Inaba, Shigeo Miyashima, Ryokei Ogawa, and Susumu Ikehara Blood Volume 91(12):4616-4623 June 15, 1998 ©1998 by American Society of Hematology

Experimental protocols. Experimental protocols. Experimental protocol 1: Female MRL/lpr mice (3 to 4 months of age) with autoimmune diseases were irradiated (8.5 Gy) and transplanted with T-cell–depleted BMCs plus bone graft of B6 mice. Experimental protocol 2: Female MRL/lpr mice with autoimmune diseases were intraperitoneally injected with 100 mg/kg CY and then lethally irradiated (5 Gy × 2 = 10 Gy for 4-hour interval) 1 day later. Four hours after the second irradiation, the bones of the B6 mice, from which the BMCs had been flushed out, were engrafted under the subcutis of the MRL/lpr mice, and the mice received 5 × 107 WBMCs from B6 mice. One day after the first BMT plus bone graft, the mice were further transplanted with B6 WBMCs (5 × 107 cells). Kenji Takeuchi et al. Blood 1998;91:4616-4623 ©1998 by American Society of Hematology

Survival rate in 6 groups. Survival rate in 6 groups. Numbers in parentheses are numbers of mice in each group. Treatment of mice is shown in the figure. Statistical analyses were performed by a logrank test, and asterisks (**) represent the P values of treated (CY/2X/Bone/2BMT) versus other groups; **P < .01, *statistical insignificance. Kenji Takeuchi et al. Blood 1998;91:4616-4623 ©1998 by American Society of Hematology

Autoantibodies in MRL/lpr mice treated with CY/2X/Bone/2BMT (Experimental protocol 2). Autoantibodies in MRL/lpr mice treated with CY/2X/Bone/2BMT (Experimental protocol 2). RFs and anti-ss DNA Abs were measured at 48 weeks after the treatment (64 weeks of age). Autoantibodies in normal C57BL/6 and untreated MRL/lpr mice were measured at 18 weeks of age. The results are expressed as the mean ± SD at 405 nm from 5 mice. Asterisks (* and **) represent Pvalues of treated versus untreated MRL/lpr mice; *P < .005 and **P < .001. Kenji Takeuchi et al. Blood 1998;91:4616-4623 ©1998 by American Society of Hematology

Immunofluorescence microscopical findings of glomerular IgG deposits in the kidneys of (A) untreated MRL/lpr at 18 weeks of age and (B) MRL/lpr mice treated with CY/2X/Bone/2BMT (56 weeks after the treatment [72 weeks of age]). Immunofluorescence microscopical findings of glomerular IgG deposits in the kidneys of (A) untreated MRL/lpr at 18 weeks of age and (B) MRL/lpr mice treated with CY/2X/Bone/2BMT (56 weeks after the treatment [72 weeks of age]). The glomerulus of an untreated MRL/lpr mouse shows the IgG deposit, whereas the glomerulus of the treated mouse shows no IgG deposit. Kenji Takeuchi et al. Blood 1998;91:4616-4623 ©1998 by American Society of Hematology

Histopathologic findings in the hindpaw joint of (A) untreated MRL/lpr at 18 weeks of age and (B) MRL/lpr mice treated with CY/2X/Bone/2BMT (56 weeks after the treatment [72 weeks of age]). Histopathologic findings in the hindpaw joint of (A) untreated MRL/lpr at 18 weeks of age and (B) MRL/lpr mice treated with CY/2X/Bone/2BMT (56 weeks after the treatment [72 weeks of age]). The joint of the untreated MRL/lpr mouse shows marked lymphoid cell infiltration and pannus formation, whereas the joint of the treated MRL/lpr mouse shows neither lymphoid cell infiltration nor pannus formation. Kenji Takeuchi et al. Blood 1998;91:4616-4623 ©1998 by American Society of Hematology

Histopathologic findings in the spleen (A), bone marrow (B), liver (C), colon (D), skin (E), and lung (F) of mice reconstituted with CD4-depleted BMCs [CY/2X/Bone/2BMT(−CD4)]. Histopathologic findings in the spleen (A), bone marrow (B), liver (C), colon (D), skin (E), and lung (F) of mice reconstituted with CD4-depleted BMCs [CY/2X/Bone/2BMT(−CD4)]. Histopathologic examination was performed 40 weeks after the treatment. The spleen and bone marrow show normal architecture with normal hematopoiesis, and there is no remarkable lymphocyte infiltration in the liver, colon, skin, or lung, indicating no GVHD. Kenji Takeuchi et al. Blood 1998;91:4616-4623 ©1998 by American Society of Hematology